Santarus, Inc. (NASDAQ:SNTS): Nationwide Law Firms Investigating Potential Breaches in Sale Process

694

Dallas, Texas 11/14/2013 (Financialstrend) – Recently, one of the nation’s largest 200 law firms, Morgan & Morgan announced to have been investigating potential claims against Santarus, Inc. (NASDAQ:SNTS)’s Board of Directors. The investigation is related to the proposed acquisition of the company by Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP).

The Allegation

Under the terms of proposed transaction valued at approximately $2.6 billion, Santarus, Inc. (NASDAQ:SNTS) stockholders will be receiving $32 per share for each share hold. Morgan & Morgan is investigating possible concerns related to breaches of fiduciary duty and other possible violations of law by Santarus, Inc. (NASDAQ:SNTS)’s Board of Directors for not acting in best interest of company’s shareholders with regards to the sale process.

Related Investigations

Among other law firms investigating the claims, Rigrodsky & Long, P.A. also announced on November 11, 2013 to have been investigating possible breaches of fiduciary duties by the Board of Directors of Santarus, Inc. (NASDAQ:SNTS) for the claims whether they failed to substantially shop the Company to obtain best possible deal for the Company’s shareholders before entering into a definitive merger agreement with Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP).

The national shareholder litigation firm, Ryan & Maniskas, LLP; Harwood Feffer LLP; Kirby McInerney LLP; Howard G. Smith; Wolf Haldenstein Adler Freeman & Herz LLP and Pomerantz Grossman Hufford Dahlstrom & Gross LLP among others are also investigating the potential claims on behalf of Santarus, Inc. (NASDAQ:SNTS) stockholders.

The Merger Agreement

The proposed agreement by Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) to acquire Santarus, Inc. (NASDAQ:SNTS) in all cash deal valued at $32.00 per share or about 39% premium over Santarus’ average closing stock price for the prior 30-trading day period. The acquisition will allow Salix to position itself as the largest U.S. gastroenterology focused pharmaceutical company while expanding its gastrointestinal product sales with Santarus’ experienced specialty sales force.

Stock Update

The Stock of Santarus, Inc. (NASDAQ:SNTS) gained 0.19% during Wednesday’s trade and closed at $31.97.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.